These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38373419)

  • 1. Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.
    Tsai YN; Wu JL; Hsu YC
    Clin Mol Hepatol; 2024 Apr; 30(2):293-296. PubMed ID: 38373419
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B core-related antigen: Are we near a treatment endpoint?
    Gupta T
    World J Gastroenterol; 2022 Jul; 28(27):3532-3534. PubMed ID: 36158266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
    Choi J
    Gut Liver; 2023 Mar; 17(2):179-180. PubMed ID: 36918269
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter regarding "Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation".
    Liaw YF
    Clin Mol Hepatol; 2024 Apr; 30(2):269-271. PubMed ID: 38295765
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
    Liu SY; Yuan C; Tong XM
    J Hepatol; 2022 Nov; 77(5):1471-1472. PubMed ID: 35863489
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
    Liaw YF; Jeng WJ; Chien RN
    Hepatology; 2024 Mar; 79(3):E97-E98. PubMed ID: 37862454
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
    Dongelmans EJ; Sonneveld MJ; Janssen HLA
    Hepatology; 2024 Mar; 79(3):E95-E96. PubMed ID: 37862458
    [No Abstract]   [Full Text] [Related]  

  • 8. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 9. [Research progress of biomarkers of hepatitis B virus and clinical significance].
    Wang X; Tang X; Han N; Tang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Dec; 40(6):1242-1248. PubMed ID: 38151949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen.
    Perrillo RP; Brunt EM
    Ann Intern Med; 1991 Jul; 115(2):113-5. PubMed ID: 2058858
    [No Abstract]   [Full Text] [Related]  

  • 11. HBV RNA, Hepatitis B Core-Related Antigen, and Quantitative Hepatitis B Surface Antigen Biomarkers to Predict Outcome of Antiviral Therapy.
    Debnath P; Rathi P
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2680-2681. PubMed ID: 33387671
    [No Abstract]   [Full Text] [Related]  

  • 12. [Imperatives to strengthen HBsAg screening and expand antiviral therapy indications on hepatitis B among the general population].
    Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):646-648. PubMed ID: 37400392
    [No Abstract]   [Full Text] [Related]  

  • 13. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance.
    Wu Y; Liu Y; Lu J; Cao Z; Jin Y; Ma L; Geng N; Ren S; Zheng Y; Shen C; Chen X
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):514-516.e2. PubMed ID: 30981007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of serum Golgi protein 73 for screening chronic hepatitis B virus infection patients needing antiviral therapy in the community.
    Duan J; Wen X; Wang H; Chen W; Gao P; Yuan Q; Zheng H; Liu Y; Wu J; Wang J; Yao M; Lu F
    Chin Med J (Engl); 2022 Nov; 135(22):2741-2743. PubMed ID: 36574219
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hepatitis B viral mutation and its clinical significance].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():167-74. PubMed ID: 15453309
    [No Abstract]   [Full Text] [Related]  

  • 16. Naturally occurring deletions/insertions in HBV core promoter tend to decrease in hepatitis B e antigen-positive chronic hepatitis B patients during antiviral therapy.
    Peng Y; Liu B; Hou J; Sun J; Hao R; Xiang K; Yan L; Zhang J; Zhuang H; Li T
    Antivir Ther; 2015; 20(6):623-32. PubMed ID: 25838313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
    Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
    J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting liver metabolism: a pathway to cure hepatitis B virus?
    Ajoyan H; Douglas MW; Tu T
    Expert Rev Gastroenterol Hepatol; 2023; 17(7):645-647. PubMed ID: 37318059
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
    Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
    Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.